Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance
Background The introduction of generic versions of drugs has often resulted in an increase in the consumption of the agents involved. In December 2001, generic ciprofloxacin was marketed in Denmark. Our objective was to evaluate, in a community setting, the effect of price on consumption of ciproflo...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2010-06, Vol.65 (6), p.1286-1291 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1291 |
|---|---|
| container_issue | 6 |
| container_start_page | 1286 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 65 |
| creator | Jensen, Ulrich S. Muller, Arno Brandt, Christian T. Frimodt-Møller, Niels Hammerum, Anette M. Monnet, Dominique L. |
| description | Background The introduction of generic versions of drugs has often resulted in an increase in the consumption of the agents involved. In December 2001, generic ciprofloxacin was marketed in Denmark. Our objective was to evaluate, in a community setting, the effect of price on consumption of ciprofloxacin and on ciprofloxacin resistance in Escherichia coli urine isolates. Methods We conducted a retrospective ecological study collecting monthly national data on the number of marketed versions and primary healthcare (PHC) sales of ciprofloxacin during January 1995–December 2005. Data were compared with a median price per defined daily dose (DDD) of ciprofloxacin during September 1999–December 2005. Yearly PHC consumption data from seven Danish counties were compared with the antimicrobial resistance profiles of PHC E. coli urine isolates. Results During 2002, the number of marketed versions increased from 3 to 10, and the median price per DDD decreased by 53%. From 2002 to 2005, the total consumption of oral ciprofloxacin in PHC increased significantly from 0.13 DDD/1000 inhabitant-days to 0.33 DDD/1000 inhabitant-days. During the same period, the frequency of ciprofloxacin resistance increased by 200%. A statistically significant correlation was found between the consumption of ciprofloxacin and the ciprofloxacin resistance rate in E. coli urine isolates, independent of the introduction of generic ciprofloxacin. Conclusions After the introduction of generic ciprofloxacin, a significant increase in the total consumption of oral ciprofloxacin in PHC was observed in Denmark. The increase in consumption was significantly correlated with ciprofloxacin resistance in E. coli obtained from urine isolates. |
| doi_str_mv | 10.1093/jac/dkq093 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_744699029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2044241821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-f341f1225fe677531b9a93e1c578fb2c586c59fc86f4821847f8a7f0317d85953</originalsourceid><addsrcrecordid>eNqF0U1rVDEUBuAgih2rG3-ABEGEwrX5uPnqTktthaogCuImZDInnUzvJNPkXqgL_3vTztiCG1c5JE8OyXkReknJO0oMP1w5f7i4vGrlIzSjvSQdI4Y-RjPCiehUL_geelbrihAihdRP0R4jXHJN5Az9OQkB_IhzwBeQoERfcU540wrALi2wz6lO680Y225DPm5KDkO-dj4mHO_k2pXfeAluGJfeFTjC4xJwgcHdXqrLuMFjbtQXcDWmi3ZUYx1d8vAcPQluqPBit-6jHx9Pvh-fdedfTz8dvz_vvKBi7ALvaaCMiQBSKcHp3DjDgXqhdJgzL7T0wgSvZeg1o7pXQTsVCKdqoYURfB-93fZtj7-aoI52HauHYXAJ8lSt6ntpDGHm_5JzQWVvVJOv_5GrPJXUvmF56yaIlqyhgy3yJddaINjdvCwl9jY828Kz2_AafrXrOM3XsLinf9Nq4M0OuOrdEEqbYawPjmlmlCbNdVvXxgzX9-euXFqpuBL27OcvKz9T8q0__WC_8BvQ97JH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>346950862</pqid></control><display><type>article</type><title>Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Jensen, Ulrich S. ; Muller, Arno ; Brandt, Christian T. ; Frimodt-Møller, Niels ; Hammerum, Anette M. ; Monnet, Dominique L.</creator><creatorcontrib>Jensen, Ulrich S. ; Muller, Arno ; Brandt, Christian T. ; Frimodt-Møller, Niels ; Hammerum, Anette M. ; Monnet, Dominique L. ; DANRES study group ; on behalf of the DANRES study group</creatorcontrib><description>Background The introduction of generic versions of drugs has often resulted in an increase in the consumption of the agents involved. In December 2001, generic ciprofloxacin was marketed in Denmark. Our objective was to evaluate, in a community setting, the effect of price on consumption of ciprofloxacin and on ciprofloxacin resistance in Escherichia coli urine isolates. Methods We conducted a retrospective ecological study collecting monthly national data on the number of marketed versions and primary healthcare (PHC) sales of ciprofloxacin during January 1995–December 2005. Data were compared with a median price per defined daily dose (DDD) of ciprofloxacin during September 1999–December 2005. Yearly PHC consumption data from seven Danish counties were compared with the antimicrobial resistance profiles of PHC E. coli urine isolates. Results During 2002, the number of marketed versions increased from 3 to 10, and the median price per DDD decreased by 53%. From 2002 to 2005, the total consumption of oral ciprofloxacin in PHC increased significantly from 0.13 DDD/1000 inhabitant-days to 0.33 DDD/1000 inhabitant-days. During the same period, the frequency of ciprofloxacin resistance increased by 200%. A statistically significant correlation was found between the consumption of ciprofloxacin and the ciprofloxacin resistance rate in E. coli urine isolates, independent of the introduction of generic ciprofloxacin. Conclusions After the introduction of generic ciprofloxacin, a significant increase in the total consumption of oral ciprofloxacin in PHC was observed in Denmark. The increase in consumption was significantly correlated with ciprofloxacin resistance in E. coli obtained from urine isolates.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkq093</identifier><identifier>PMID: 20363806</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Anti-Bacterial Agents - economics ; Anti-Bacterial Agents - therapeutic use ; antibiotic prescriptions ; Antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Chemotherapy ; Ciprofloxacin - economics ; Ciprofloxacin - therapeutic use ; Denmark ; drug monitoring ; Drug resistance ; Drug Resistance, Bacterial ; Drug use ; Drug Utilization - statistics & numerical data ; Drugs, Generic - economics ; Drugs, Generic - therapeutic use ; Escherichia coli ; Escherichia coli - drug effects ; Escherichia coli - isolation & purification ; fluoroquinolones ; Generic drugs ; Humans ; Medical sciences ; Microbial Sensitivity Tests ; Pharmacology. Drug treatments ; Prices ; Primary care ; Primary Health Care ; Retrospective Studies ; Urine - microbiology</subject><ispartof>Journal of antimicrobial chemotherapy, 2010-06, Vol.65 (6), p.1286-1291</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright Oxford Publishing Limited(England) Jun 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c515t-f341f1225fe677531b9a93e1c578fb2c586c59fc86f4821847f8a7f0317d85953</citedby><cites>FETCH-LOGICAL-c515t-f341f1225fe677531b9a93e1c578fb2c586c59fc86f4821847f8a7f0317d85953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22829780$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20363806$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jensen, Ulrich S.</creatorcontrib><creatorcontrib>Muller, Arno</creatorcontrib><creatorcontrib>Brandt, Christian T.</creatorcontrib><creatorcontrib>Frimodt-Møller, Niels</creatorcontrib><creatorcontrib>Hammerum, Anette M.</creatorcontrib><creatorcontrib>Monnet, Dominique L.</creatorcontrib><creatorcontrib>DANRES study group</creatorcontrib><creatorcontrib>on behalf of the DANRES study group</creatorcontrib><title>Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Background The introduction of generic versions of drugs has often resulted in an increase in the consumption of the agents involved. In December 2001, generic ciprofloxacin was marketed in Denmark. Our objective was to evaluate, in a community setting, the effect of price on consumption of ciprofloxacin and on ciprofloxacin resistance in Escherichia coli urine isolates. Methods We conducted a retrospective ecological study collecting monthly national data on the number of marketed versions and primary healthcare (PHC) sales of ciprofloxacin during January 1995–December 2005. Data were compared with a median price per defined daily dose (DDD) of ciprofloxacin during September 1999–December 2005. Yearly PHC consumption data from seven Danish counties were compared with the antimicrobial resistance profiles of PHC E. coli urine isolates. Results During 2002, the number of marketed versions increased from 3 to 10, and the median price per DDD decreased by 53%. From 2002 to 2005, the total consumption of oral ciprofloxacin in PHC increased significantly from 0.13 DDD/1000 inhabitant-days to 0.33 DDD/1000 inhabitant-days. During the same period, the frequency of ciprofloxacin resistance increased by 200%. A statistically significant correlation was found between the consumption of ciprofloxacin and the ciprofloxacin resistance rate in E. coli urine isolates, independent of the introduction of generic ciprofloxacin. Conclusions After the introduction of generic ciprofloxacin, a significant increase in the total consumption of oral ciprofloxacin in PHC was observed in Denmark. The increase in consumption was significantly correlated with ciprofloxacin resistance in E. coli obtained from urine isolates.</description><subject>Anti-Bacterial Agents - economics</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>antibiotic prescriptions</subject><subject>Antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Ciprofloxacin - economics</subject><subject>Ciprofloxacin - therapeutic use</subject><subject>Denmark</subject><subject>drug monitoring</subject><subject>Drug resistance</subject><subject>Drug Resistance, Bacterial</subject><subject>Drug use</subject><subject>Drug Utilization - statistics & numerical data</subject><subject>Drugs, Generic - economics</subject><subject>Drugs, Generic - therapeutic use</subject><subject>Escherichia coli</subject><subject>Escherichia coli - drug effects</subject><subject>Escherichia coli - isolation & purification</subject><subject>fluoroquinolones</subject><subject>Generic drugs</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Pharmacology. Drug treatments</subject><subject>Prices</subject><subject>Primary care</subject><subject>Primary Health Care</subject><subject>Retrospective Studies</subject><subject>Urine - microbiology</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0U1rVDEUBuAgih2rG3-ABEGEwrX5uPnqTktthaogCuImZDInnUzvJNPkXqgL_3vTztiCG1c5JE8OyXkReknJO0oMP1w5f7i4vGrlIzSjvSQdI4Y-RjPCiehUL_geelbrihAihdRP0R4jXHJN5Az9OQkB_IhzwBeQoERfcU540wrALi2wz6lO680Y225DPm5KDkO-dj4mHO_k2pXfeAluGJfeFTjC4xJwgcHdXqrLuMFjbtQXcDWmi3ZUYx1d8vAcPQluqPBit-6jHx9Pvh-fdedfTz8dvz_vvKBi7ALvaaCMiQBSKcHp3DjDgXqhdJgzL7T0wgSvZeg1o7pXQTsVCKdqoYURfB-93fZtj7-aoI52HauHYXAJ8lSt6ntpDGHm_5JzQWVvVJOv_5GrPJXUvmF56yaIlqyhgy3yJddaINjdvCwl9jY828Kz2_AafrXrOM3XsLinf9Nq4M0OuOrdEEqbYawPjmlmlCbNdVvXxgzX9-euXFqpuBL27OcvKz9T8q0__WC_8BvQ97JH</recordid><startdate>20100601</startdate><enddate>20100601</enddate><creator>Jensen, Ulrich S.</creator><creator>Muller, Arno</creator><creator>Brandt, Christian T.</creator><creator>Frimodt-Møller, Niels</creator><creator>Hammerum, Anette M.</creator><creator>Monnet, Dominique L.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20100601</creationdate><title>Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance</title><author>Jensen, Ulrich S. ; Muller, Arno ; Brandt, Christian T. ; Frimodt-Møller, Niels ; Hammerum, Anette M. ; Monnet, Dominique L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-f341f1225fe677531b9a93e1c578fb2c586c59fc86f4821847f8a7f0317d85953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Anti-Bacterial Agents - economics</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>antibiotic prescriptions</topic><topic>Antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Ciprofloxacin - economics</topic><topic>Ciprofloxacin - therapeutic use</topic><topic>Denmark</topic><topic>drug monitoring</topic><topic>Drug resistance</topic><topic>Drug Resistance, Bacterial</topic><topic>Drug use</topic><topic>Drug Utilization - statistics & numerical data</topic><topic>Drugs, Generic - economics</topic><topic>Drugs, Generic - therapeutic use</topic><topic>Escherichia coli</topic><topic>Escherichia coli - drug effects</topic><topic>Escherichia coli - isolation & purification</topic><topic>fluoroquinolones</topic><topic>Generic drugs</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Pharmacology. Drug treatments</topic><topic>Prices</topic><topic>Primary care</topic><topic>Primary Health Care</topic><topic>Retrospective Studies</topic><topic>Urine - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jensen, Ulrich S.</creatorcontrib><creatorcontrib>Muller, Arno</creatorcontrib><creatorcontrib>Brandt, Christian T.</creatorcontrib><creatorcontrib>Frimodt-Møller, Niels</creatorcontrib><creatorcontrib>Hammerum, Anette M.</creatorcontrib><creatorcontrib>Monnet, Dominique L.</creatorcontrib><creatorcontrib>DANRES study group</creatorcontrib><creatorcontrib>on behalf of the DANRES study group</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jensen, Ulrich S.</au><au>Muller, Arno</au><au>Brandt, Christian T.</au><au>Frimodt-Møller, Niels</au><au>Hammerum, Anette M.</au><au>Monnet, Dominique L.</au><aucorp>DANRES study group</aucorp><aucorp>on behalf of the DANRES study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2010-06-01</date><risdate>2010</risdate><volume>65</volume><issue>6</issue><spage>1286</spage><epage>1291</epage><pages>1286-1291</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>Background The introduction of generic versions of drugs has often resulted in an increase in the consumption of the agents involved. In December 2001, generic ciprofloxacin was marketed in Denmark. Our objective was to evaluate, in a community setting, the effect of price on consumption of ciprofloxacin and on ciprofloxacin resistance in Escherichia coli urine isolates. Methods We conducted a retrospective ecological study collecting monthly national data on the number of marketed versions and primary healthcare (PHC) sales of ciprofloxacin during January 1995–December 2005. Data were compared with a median price per defined daily dose (DDD) of ciprofloxacin during September 1999–December 2005. Yearly PHC consumption data from seven Danish counties were compared with the antimicrobial resistance profiles of PHC E. coli urine isolates. Results During 2002, the number of marketed versions increased from 3 to 10, and the median price per DDD decreased by 53%. From 2002 to 2005, the total consumption of oral ciprofloxacin in PHC increased significantly from 0.13 DDD/1000 inhabitant-days to 0.33 DDD/1000 inhabitant-days. During the same period, the frequency of ciprofloxacin resistance increased by 200%. A statistically significant correlation was found between the consumption of ciprofloxacin and the ciprofloxacin resistance rate in E. coli urine isolates, independent of the introduction of generic ciprofloxacin. Conclusions After the introduction of generic ciprofloxacin, a significant increase in the total consumption of oral ciprofloxacin in PHC was observed in Denmark. The increase in consumption was significantly correlated with ciprofloxacin resistance in E. coli obtained from urine isolates.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>20363806</pmid><doi>10.1093/jac/dkq093</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2010-06, Vol.65 (6), p.1286-1291 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_744699029 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | Anti-Bacterial Agents - economics Anti-Bacterial Agents - therapeutic use antibiotic prescriptions Antibiotics Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Chemotherapy Ciprofloxacin - economics Ciprofloxacin - therapeutic use Denmark drug monitoring Drug resistance Drug Resistance, Bacterial Drug use Drug Utilization - statistics & numerical data Drugs, Generic - economics Drugs, Generic - therapeutic use Escherichia coli Escherichia coli - drug effects Escherichia coli - isolation & purification fluoroquinolones Generic drugs Humans Medical sciences Microbial Sensitivity Tests Pharmacology. Drug treatments Prices Primary care Primary Health Care Retrospective Studies Urine - microbiology |
| title | Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T04%3A19%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20generics%20on%20price%20and%20consumption%20of%20ciprofloxacin%20in%20primary%20healthcare:%20the%20relationship%20to%20increasing%20resistance&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Jensen,%20Ulrich%20S.&rft.aucorp=DANRES%20study%20group&rft.date=2010-06-01&rft.volume=65&rft.issue=6&rft.spage=1286&rft.epage=1291&rft.pages=1286-1291&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/dkq093&rft_dat=%3Cproquest_cross%3E2044241821%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=346950862&rft_id=info:pmid/20363806&rfr_iscdi=true |